Drugs / BIIB100
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03945279 | May 2019 → Jun 2021 | amyotrophic lateral sclerosis | Biogen | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BIIB100 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03945279 ↗ |
| Route | Oral | “Participants will receive single oral dose of BIIB100 on Day 1.” NCT03945279 ↗ |